RESEARCH TRIANGLE PARK – Liquidia Technologies, Inc. will be submitting a new drug application to the Food and Drug Administration for LIQ861 early in the first quarter of 2020, according to a recent Securities and Exchange Commission filing.

The filing indicates that the company completed clinical tests for its Phase 3 development program in its investigational treatment plan for pulmonary arterial hypertension.

[In August, Liquidia filed a notice with the SEC that it could raise as much as $200 million.]

A meeting with the FDA regarding the chemistry, manufacturing and controls aspects of the plan has already been conducted. Another meeting concerning the clinical and nonclinical contents of the NDA is expected to be held in November.

Liquidia Technologies is a bio-pharmaceutical company headquartered in Morrisville. Shares of Liquidia were trading at $3.62 on Friday, up three cents.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s Hussman School of Journalism and Media.